久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
聯(lián)系熱線
  • 聯(lián)系人:方經(jīng)理
  • 電 話:027-65279366
  • 郵箱:products@biolabreagent.com
  • 地 址:武漢市東湖新技術(shù)開發(fā)區(qū)神墩四路666號C棟

恩弗利單抗,Envafolimab, AntibodySystem Laboratories

發(fā)表時間:2023-05-09

標(biāo)題:恩弗利單抗,Envafolimab,CAS: 2102192-68-5,AntibodySystem Laboratories

貨號:DHJ70104

產(chǎn)品鏈接:http://www.atagenix.com/product_detail-75183.html

別名:KN-035, CAS: 2102192-68-5

簡介:

恩弗利單抗 Envafolimab (ASC 22; KN 035) 是人源化的單域抗 PD-L1 抗體的重組蛋白。Envafolimab 是由抗 PD-L1 結(jié)構(gòu)域與人 IgG1 抗體的 Fc 片段融合而成。Envafolimab 阻斷 PD-L1 和 PD-1 之間的相互作用,IC50 值為 5.25?nM。Envafolimab 具有研究實體瘤的潛力。

貨號DHJ70104

產(chǎn)品品牌Antibodysystem

通用名;Envafolimab

純度>95% by SDS-PAGE.

濃度1mg/ml

Formulationicon0.01M PBS, pH 7.4.

內(nèi)毒素Please contact with the lab for this information.

別名KN-035

靶點;物種Human CD274/PD-L1/B7-H1

種類Chimeric

受體鑒定(VH-CH2-CH3)2

CAS2102192-68-5

存儲條件

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻:

Envafolimab: First Approval. PMID: 35122636
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. PMID: 34154614
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. PMID: 33973293
Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors. PMID: 36124972
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. PMID: 35932387
Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report. PMID: 36874434
Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia. PMID: 36998453
Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers. PMID: 35347438
Residue-specific binding mechanisms of PD-L1 to its monoclonal antibodies by computational alanine scanning. PMID: 34259259
Noninvasive Imaging of Tumor PD-L1 Expression Using [99mTc]Tc-Labeled KN035 with SPECT/CT. PMID: 36541699

聯(lián)系方式
手機:18162686757
微信掃一掃
东乡| 兴和县| 沾益县| 烟台市| 孝昌县| 南澳县| 富蕴县| 珠海市| 浦北县| 遵义县| 安泽县| 海阳市| 岳西县| 蛟河市| 柳江县| 夏津县| 南开区| 仁布县| 屏东市| 宁化县| 五指山市| 拜泉县| 苍南县| 张家界市| 樟树市| 开江县| 颍上县| 太仆寺旗| 吴川市| 岳阳市| 台州市| 合江县| 米易县| 广安市| 大新县| 娱乐| 四子王旗| 鄱阳县| 闻喜县| 满城县| 灵台县|